Siga Technologies (NASDAQ:SIGA) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Siga Technologies (NASDAQ:SIGA) from a strong-buy rating to a hold rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “hold (c+)” rating on shares of Siga Technologies in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, the company currently has a consensus rating of “Hold”.

Siga Technologies Stock Down 1.7%

Siga Technologies stock opened at $5.90 on Friday. Siga Technologies has a 52-week low of $4.95 and a 52-week high of $9.62. The company has a market cap of $422.50 million, a P/E ratio of 5.22 and a beta of 0.93. The business has a 50-day simple moving average of $8.27 and a two-hundred day simple moving average of $7.41.

Siga Technologies (NASDAQ:SIGA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $2.62 million during the quarter. Siga Technologies had a return on equity of 40.52% and a net margin of 45.73%. Research analysts anticipate that Siga Technologies will post 1.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SIGA. Jacobs Levy Equity Management Inc. raised its holdings in Siga Technologies by 5.7% during the third quarter. Jacobs Levy Equity Management Inc. now owns 463,705 shares of the company’s stock valued at $4,243,000 after acquiring an additional 24,851 shares during the period. PharVision Advisers LLC purchased a new position in Siga Technologies in the 3rd quarter worth approximately $138,000. Sherbrooke Park Advisers LLC purchased a new position in Siga Technologies in the 3rd quarter worth approximately $125,000. Qube Research & Technologies Ltd bought a new position in Siga Technologies in the 3rd quarter worth approximately $423,000. Finally, Prelude Capital Management LLC purchased a new stake in Siga Technologies during the 3rd quarter valued at approximately $180,000. Institutional investors own 55.40% of the company’s stock.

Siga Technologies Company Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.